Literature DB >> 3244661

Dynamics of bromodeoxyuridine incorporation into DNA of squamous carcinoma cells during mid and late logarithmic growth.

A Shapira1, J G Wagner, I S Wollner, J Maybaum, P L Stetson, W D Ensminger, T E Carey.   

Abstract

Head and neck squamous carcinoma cell lines, UM-SCC 1, 5, 9, 11B, and 14B, were exposed in vitro to bromodeoxyuridine (BUdR) during logarithmic growth to determine the effects of drug concentration (0.01 to 10 microM) and duration of exposure (3, 7, and 10 days) on cell growth and on incorporation of BUdR into DNA. Concentrations of less than 1.0 microM were not growth inhibitory except with UM-SCC-11B. After 10 days of exposure to 5 microM BUdR, survival fractions for all lines ranged from 2 to 65% of controls. Replacement of thymidine by BUdR in DNA was assessed by gas chromatography/mass spectroscopy. Percentage replacement (% R) was described by the equation % R = 100 (C/t)s/[(C/t)50s + (C/t)s], where C is the concentration of BUdR (microM), t is the time in days, s is a constant, and (C/t)50 is a constant corresponding to % R = 50%. BUdR incorporation reached a time- and concentration-dependent maximum that, after 3 to 7 days of culture in 10 microM BUdR, ranged from 30 to 60% R. Subsequently, % R declined with time even though the cells were fed daily with fresh BUdR-containing medium.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244661     DOI: 10.1023/a:1015925509778

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Increase in radiosensitivity to ionizing radiation related to replacement of thymidine in mammalian cells with 5-bromodeoxyuridine.

Authors:  W C Dewey; R M Humphrey
Journal:  Radiat Res       Date:  1965-12       Impact factor: 2.841

2.  Further studies on biological properties of mammalian cell lines resistant to 5-bromodeoxyuridine.

Authors:  R M Humphrey; T C Hsu
Journal:  Tex Rep Biol Med       Date:  1965-06

3.  Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs.

Authors:  T J Kinsella; P P Dobson; J B Mitchell; A J Fornace
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-05       Impact factor: 7.038

4.  In vitro correlation of drug concentrations and radiosensitization in combination therapy with 5-bromo-2'-deoxyuridine, methotrexate, and radiation.

Authors:  S Wakisaka
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

5.  Identification of bromodeoxyuridine in malignant and normal cells following therapy: relationship to complications.

Authors:  G Morstyn; T Kinsella; S M Hsu; A Russo; H Gratzner; J Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-08       Impact factor: 7.038

6.  A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.

Authors:  T J Kinsella; A Russo; J B Mitchell; J Rowland; J Jenkins; J Schwade; C E Myers; J M Collins; J Speyer; P Kornblith
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-01       Impact factor: 7.038

7.  Antibodies to human squamous cell carcinoma.

Authors:  T E Carey; K A Kimmel; D R Schwartz; D E Richter; S R Baker; C J Krause
Journal:  Otolaryngol Head Neck Surg       Date:  1983-10       Impact factor: 3.497

8.  Growth inhibition of laryngeal UM-SCC cell lines by tamoxifen. Comparison with effects on the MCF-7 breast cancer cell line.

Authors:  A Shapira; E Virolainen; J J Jameson; S J Ossakow; T E Carey
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1986-11

9.  Analysis of bromodeoxyuridine incorporation into DNA: comparison of gas chromatographic/mass spectrometric, CsCl gradient sedimentation, and specific radioactivity methods.

Authors:  J Maybaum; M G Kott; N J Johnson; W D Ensminger; P L Stetson
Journal:  Anal Biochem       Date:  1987-02-15       Impact factor: 3.365

10.  Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity.

Authors:  B DJORDJEVIC; W SZYBALSKI
Journal:  J Exp Med       Date:  1960-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.